Status:
RECRUITING
Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study
Lead Sponsor:
Centre Francois Baclesse
Conditions:
Endometrial Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This study comprises 3 stages: 1. Collection of tumor and blood samples. 2. Creation of organoid models based on tumor samples. 3. Development of functional tests to predict clinical response to trea...
Eligibility Criteria
Inclusion
- Patient aged 18 years or more
- Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment.
- Patient with localized endometrial cancer, presenting:
- A high-grade endometrioid histological type and/or
- P53 mutation and/or
- a non-endometrioid histological type regardless of P53 status.
- Patient affiliated to a social security scheme
- Information and signature of informed consent prior to any specific study procedure
Exclusion
- Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin).
- Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.
Key Trial Info
Start Date :
November 21 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 15 2027
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT06603506
Start Date
November 21 2024
End Date
October 15 2027
Last Update
November 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre François Baclesse
Caen, France